Genetic Agency Technology Conference (GATC) 2025
A one-day gathering for therapeutic developers, technologists, AI pioneers, and entrepreneurs, together with patients and their advocates, to co-create the future of genetic medicine
Boston Seaport (Westin)
About GATC
We are working to build a world with “genetic agency”: a person’s ability to make informed choices and take action at the DNA level to live a healthier life. It’s a term we’ve started using to highlight the importance of creating therapeutic options where none exist today, and to recognize the efforts of patients and their families who work to develop these medicines themselves rather than to give up hope. To help make this happen, Dyno is hosting a Genetic Agency Technology Conference (GATC) in Boston on November 11.
The conference is inspired by a vision of the future with patient-empowering genetic technologies that are safe, effective and accessible to all — and the recognition that we will need to overcome major challenges, technological and otherwise, for all of these treatments to become a reality. This future can’t be realized by any one actor alone — it requires a community working together with pace to turn powerful emerging technologies into patient impact.
At GATC we’re bringing together leaders from various sectors: therapeutic developers, technologists, AI pioneers, and entrepreneurs along with patients and their advocates. Topics at this meeting will include state of the art AI for sequence design, along with gene editing and gene delivery as enabling technologies, and other areas of interest to attendees such as preclinical development, manufacturing and regulatory pathways.
Compared to other conferences, GATC puts greater emphasis on technological frontiers, firmly grounded in patient impact and including highly participatory sessions emphasizing conversation and connnection. Our assumption is that everyone who attends comes with expertise and a goal.
Why Attend
Empower
Elevate the voices of patients and their advocates as critical experts shaping the next generation of genetic technologies
Connect
Build lasting relationships across the gene therapy ecosystem that are rooted in a shared commitment to advancing genetic agency
Engage
Spark meaningful and candid conversations to challenge norms and bridge the gap between technology innovation and real patient impact
Activate
Gain actionable insights to translate learnings into better treatment options today and goals for future technology development that align with patient priorities
Featured Speakers
Our exciting lineup of speakers includes:
George Church, PhD
Founding Core Faculty and Synthetic Biology Lead at the Wyss Institute
Sonia Vallabh, PhD
Director of Prion Therapeutic Science at the Broad Institute
Federico Mingozzi, PhD
CEO of Nava Therapeutics and ASGCT Treasurer
Terence Flotte, MD
Provost, Dean, Professor at UMass Chan Medical School and ASGCT President
Victoria Gray
First patient treated with CRISPR gene editing therapy for Sickle Cell Disease
James Wilson, MD, PhD
Founder and CEO of Gemma Biotherapeutics and Franklin Biolabs
Sylke Poehling, PhD
CEO of Spark Therapeutics (Roche wholly owned entity) and SVP, Global Head of Therapeutic Modalities at Roche
Jude Samulski, PhD
Co-founder of AskBio and M34 Inc
Allyson Berent, DVM, DACVIM
CSO of Foundation for Angelman Syndrome Therapeutics
Aravind Asokan, PhD
Professor Duke University School of Medicine, serial biotech entrepreneur
Cory Sago, PhD
Founder and CEO of Amplitude Therapeutics
Dan Gibbs, PhD
Co-founder and CEO of Cirsium Biosciences
Gaurav Venkataraman, PhD
Co-founder and CEO of Trisk Bio
Jacob Becraft, PhD
Co-founder and CEO of Strand Therapeutics
John Finn, PhD
CSO of Basecamp Research
Kartik Ramamoorthi, PhD
Co-founder and CEO of Encoded Therapeutics
Martin Borch Jensen, PhD
Co-founder and CSO of Gordian Biotechnology
Laura Lande-Diner, PhD
Managing Partner, Jefferson Life Sciences, serial biotech entrepreneur
Le Cong, PhD
Assistant Professor at Stanford University School of Medicine
Omar Abudayyeh, PhD
Assistant Professor of Medicine at Harvard Medical School, Co-Director of the Abudayyeh-Gootenberg Lab, and Co-founder of multiple biotechs
Pranam Chatterjee, PhD
Assistant Professor at University of Pennsylvania and Co-founder of multiple biotechs
Jonathan Gootenberg, PhD
Assistant Professor of Medicine at Harvard Medical School, Co-Director of the Abudayyeh-Gootenberg Lab, and Co-founder of multiple biotechs
Winston Yan, MD, PhD
Founding President of N=1 Collaborative and Co-founder of Arbor Biotechnologies
Yogev Debbi, MBA
Co-founder and CEO of Mana.bio
Schedule
November 11, 2025
8:00 am - 5:00 pm
Conference Programming
5:00 pm - 7:00 pm
Reception and Happy Hour Social
FAQ
Interested in taking part in GATC 2025?
GATC is an invitation-only event, though a limited number of spots are available for those who apply to attend. We welcome anyone interested to submit an application, no later than Oct 10.
